Literature DB >> 29251783

Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Elderly Antipsychotic-Treated Women With Type 2 Diabetes and Subclinical Hypothyroidism: A Preliminary Study.

Robert Krysiak1, Witold Szkróbka1, Bogusław Okopień1.   

Abstract

Metformin was found to reduce elevated serum thyrotropin levels, and this effect was partially determined by endogenous dopaminergic tone. The aim of this study was to compare the effect of metformin treatment on hypothalamic-pituitary-thyroid axis activity in elderly women with subclinical hypothyroidism treated with antipsychotic agents and not receiving this drug. The study population consisted of 34 elderly women with subclinical hypothyroidism, 16 of whom received antipsychotic drugs. Because of coexistent type 2 diabetes, these women were treated with metformin (2.55-3 g daily). Glucose homeostasis markers as well as serum levels of thyrotropin, free thyroid hormones and prolactin were measured at the beginning of the study and 6 months later. Thirty women completed the study. With the exception of prolactin, baseline serum levels of the assessed hormones were comparable in both study groups. Although metformin reduced serum thyrotropin levels in both groups, this effect was more pronounced in the antipsychotic-treated than in the antipsychotic-naive patients. The effect on serum prolactin was observed only in antipsychotic-treated patients. The impact on serum thyrotropin levels correlated with improvement in insulin sensitivity and with a reduction in prolactin levels. Free thyroxine and free triiodothyronine remained at a similar level throughout the study. The obtained results indicate that metformin reduces serum thyrotropin levels in elderly women, and this effect is particularly pronounced in women with diminished dopaminergic transmission.
© 2017, The American College of Clinical Pharmacology.

Entities:  

Keywords:  antipsychotics; diabetes mellitus; hypothalamic-pituitary-thyroid axis; metformin; thyroiditi

Mesh:

Substances:

Year:  2017        PMID: 29251783     DOI: 10.1002/jcph.1048

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Effect of metformin on thyroid function tests in patients with subclinical hypothyroidism: an open-label randomised controlled trial.

Authors:  R Palui; J Sahoo; S Kamalanathan; S S Kar; K Sridharan; H Durgia; H Raj; M Patil
Journal:  J Endocrinol Invest       Date:  2019-05-24       Impact factor: 4.256

2.  Association of Phthalate Exposure with Thyroid Function and Thyroid Homeostasis Parameters in Type 2 Diabetes.

Authors:  Yi Chen; Wen Zhang; JingSi Chen; Ningjian Wang; Chi Chen; Yuying Wang; Heng Wan; Bo Chen; Yingli Lu
Journal:  J Diabetes Res       Date:  2021-10-27       Impact factor: 4.011

3.  Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial.

Authors:  Cuifang Zhu; Ruofan Li; Mingliang Ju; Xudong Xiao; Ti-Fei Yuan; Zhixing Jin; Jing Zhao
Journal:  Front Mol Neurosci       Date:  2022-05-26       Impact factor: 6.261

4.  Diabetic vasculopathy: macro and microvascular injury.

Authors:  Roberto I Mota; Samuel E Morgan; Edward M Bahnson
Journal:  Curr Pathobiol Rep       Date:  2020-01-27

5.  Thyroid Parameters and Kidney Disorder in Type 2 Diabetes: Results from the METAL Study.

Authors:  Yi Chen; Wen Zhang; Ningjian Wang; Yuying Wang; Chiyu Wang; Heng Wan; Yingli Lu
Journal:  J Diabetes Res       Date:  2020-03-28       Impact factor: 4.011

6.  A breakthrough-like effect of metformin reduces peripheral resistance to triiodothyronine in euthyroid, non-insulin-resistant, type 2 diabetic patients.

Authors:  Melinda Kertész; Szilárd Kun; Eszter Sélley; Zsuzsanna Nagy; Tamás Kőszegi; István Wittmann
Journal:  Endocr Connect       Date:  2021-07-21       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.